- Home
- GLPG vs SUPX Comparison
GLPG vs SUPX Comparison
Compare GLPG & SUPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLPG | SUPX |
|---|---|---|
| Founded | 1999 | 2021 |
| Country | Belgium | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2005 | 2024 |
Fundamental Metrics
Financial Performance| Metric | GLPG | SUPX |
|---|---|---|
| Price | $32.32 | $13.90 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $31.33 | N/A |
| AVG Volume (30 Days) | 86.3K | ★ 438.5K |
| Earning Date | 11-05-2025 | 10-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $336,643,201.00 | $3,596,575.00 |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 10.31 | ★ 23.88 |
| 52 Week Low | $22.36 | $2.75 |
| 52 Week High | $37.78 | $76.50 |
Technical Indicators
Market Signals| Indicator | GLPG | SUPX |
|---|---|---|
| Relative Strength Index (RSI) | 56.94 | 26.61 |
| Support Level | $30.73 | $16.03 |
| Resistance Level | $32.75 | $21.31 |
| Average True Range (ATR) | 0.60 | 2.73 |
| MACD | 0.07 | 0.39 |
| Stochastic Oscillator | 78.52 | 1.69 |
Price Performance
Historical ComparisonAbout GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About SUPX Super X AI Technology Limited Ordinary Shares
Super X AI Technology Ltd is an AI infrastructure solutions provider. Through its subsidiaries, SuperX offers a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, High-Voltage Direct Current (HVDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. The Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments.